MITSUCHEMPLAST Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹8.61 Cr
verification pending
Revenue YoY
6.92%
reported change
EBITDA
₹9.54 Cr
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Mitsu Chem Plast delivered a standout Q3 FY26 with EBITDA surging 73% YoY to ₹9.54 crore, expanding margins by 426bps to 11.1% — driven by operational efficiency, improved product mix, and better sales realizations. Revenue from operations grew modest 6.92% to ₹8.61 crore. The sharp margin improvement reflects successful customer mix optimization toward higher-margin niche products (16% of revenue) and disciplined cost management. Management targets 8-10% EBITDA margin as a "reasonable" structural range, with aspiration toward 15% at scale. The company's ₹1,000 crore FY28 revenue target requires nearly 2x capacity expansion (current ~29,000 MT to ~35,000 MT), requiring meaningful capex. However, FY27 growth guidance aligns with historical ~20% run-rate rather than the 35-40% CAGR needed for the FY28 target — raising execution risk. Export (2.5% of revenue, 17 countries) and healthcare furniture (Fernastra brand) are key growth vectors. Working capital cycle at 70 days and debt at ₹63-64 crore remain manageable. Investor concern exists around feasibility of doubling revenue in two years given historical 18-19% CAGR growth.
Colored figures show movement against the previous available record.
Guidance to track
- Management stated 8-10% EBITDA margin is 'reasonable' for the current business mix of commodity and niche products. With operational efficiency and scale, they aspire to 8-15% range at higher turnover.
- Long-term goal requires nearly doubling capacity to ~35,000 MT (from ~29,000 MT currently) and approximately doubling gross block. Capex requirements to be announced as plans are finalized.
- Management guided that FY27 growth will be 'almost in the same range' as historical ~20% CAGR, with more focus on profitability rather than aggressive top-line expansion.
- At 1,000 crore revenue scale, niche products (healthcare furniture components) expected to remain at 15-20% of revenue, expanding in absolute terms alongside commodity products.
Risks flagged
- The target requires 35-40% CAGR versus historical 18-19% growth. An investor explicitly questioned the math, noting FY26 may end at ~₹400 crore requiring doubling in two years. Management acknowledged the suggestion to provide clearer path in next quarter.
- 80% of business comes from just 30-35 customers. Any loss of a major customer or slowdown in their orders could materially impact revenue. Orders are typically only one-month tenures due to price volatility.
- Management admitted it takes 'more than a month' for price increases to be passed through to customers. During rising raw material cycles, temporary margin compression occurs before pricing catches up.
- Doubling gross block to reach 1,000 crore requires ₹50-100+ crore investment. When asked about funding plans, management deflected, saying plans are 'on paper' and will be announced after board approval. Future equity raise not ruled out.
Key quotes
- So I think 8 to 10% is a quite reasonable amount because we have both mix commodity and niche item. So I think 8 to 10% is quite accepted but we are always trying for the new innovation things because we have also a niche product.
- I think your calculation is perfect right? Yes, definitely. But in plastics always we have to go with the major machinery. All the current plants are saturated right now. So we can't expand too much in the same premises. So obviously we have to go for expansion.
- I think the FY28 guidance looks little unrealistic. So sir maybe you could come up with more clearer path to that 1,000 cr. We'll try to, I think it's a good suggestion and we'll try to do that.
Research modules